中国组织工程研究

中国组织工程研究 ›› 2012, Vol. 16 ›› Issue (38): 7145-7150.doi: 10.3969/j.issn.2095-4344.2012.38.024

• 生物材料综述 biomaterial review • 上一篇    下一篇

壳聚糖及其衍生物作为纳米药物载体的研究与应用

唐红波1，冯 欣1，张 彤2，刘玲蓉2，张其清2   

  1. 1首都医科大学附属北京妇产医院药剂科，北京市 100007
    2中国医学科学院生物医学工程研究所，天津市生物材料重点实验室，天津市 300192
  • 收稿日期:2012-01-19 修回日期:2012-03-02 出版日期:2012-09-16 发布日期:2012-09-16
  • 作者简介:唐红波☆，女，1977年出生，湖南省长沙县人，2010年中国医学科学院&北京协和医学院毕业，博士，主管药师，主要从事妇科肿瘤靶向纳米药物和医院药学方面的研究。 tanghongbo77@gmail.com

Chitosan and its ramifications as nano-drug carriers

Tang Hong-bo1, Feng Xin1, Zhang Tong2, Liu Ling-rong2, Zhang Qi-qing2   

  1. 1Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital Affiliated to Capital Medical University, Beijing 100007, China
    2Institute of Biomedical Engineering, Chinese Academy of Medical Science, the Key Laboratory of Biomedical Materials of Tianjin, Tianjin 300192, China
  • Received:2012-01-19 Revised:2012-03-02 Online:2012-09-16 Published:2012-09-16
  • About author:Tang Hong-bo☆, Doctor, Pharmacist- in-charge, Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital Affiliated to Capital Medical University, Beijing 100007, China tanghongbo77@ gmail.com

PDF

1003

被引次数

13

摘要：

背景：壳聚糖由于其独特的优点在药物载体研究领域中受到越来越多的关注。
目的：综述壳聚糖基纳米药物载体的体内生物效应及安全性研究，包括其药效研究、药物代谢、组织分布以及体内毒性。
方法：应用计算机检索CNKI、万方数据库和PubMed数据库中1998-01/2010-05关于以壳聚糖及其衍生物为材料制备的纳米粒子和载药纳米粒子体内药效学、药代动力学和毒性试验的文章，中文以“壳聚糖”和“纳米粒子”和“体内”或“药效”或“药代动力学”或“组织分布”或“毒性”为主题词，英文以“chitosan and nanoparticle and in vivo”或“chitosan and nanoparticle and pharcodynamic or pharmacokinetic or biodistribution or toxicity”为关键词进行检索。选择文章内容与纳米粒子体内实验相关，同一领域文献则选择近期发表或发表在权威杂志文章。初检得到166篇文献，根据纳入标准选择43篇文章进行综述。
结果与结论：从所检索到的文献进行总结分析，壳聚糖及其衍生物可作为蛋白类、细胞毒类和核酸类药物及诊断试剂等的载体，其载药纳米粒子与原型药物相比，显示出更长的体内循环时间、更好的药效和更小的毒副作用，体内药效和组织分布等生物效应和安全性均不同，研究方法也有所不同。

关键词: 壳聚糖, 纳米药物载体, 体内, 生物效应, 安全性

Abstract:

BACKGROUND: Chitosan has been paid much attention due to its unique advantages in the research field of drug carrier.
OBJECTIVE: To review the in vivo bioeffect and safety of chitosan-based nano-drug carrier, including drug efficacy, drug metabolism, tissue distribution and in vivo toxicity studies.
METHODS: CNKI, Wanfang and PubMed databases were searched by computer for papers concerning in vivo pharmacodynamic, pharmacokinetics and toxicity tests of nanoparticles and nano-drug carriers prepared by chitosan and its ramifications (1998-01/2010-05). The key words were “chitosan, nano-particle, in vivo” or “drug action” or “pharmacokinetics” or “ tissue distribution or toxicity” in Chinese, and “chitosan and nanoparticle and in vivo” or “chitosan and nanoparticle and pharcodynamic or pharmacokinetic or biodistribution or toxicity” in English. Papers related to in vivo experiments of nanoparticles, and published recently and authoritatively in the same field were included. Totally 166 papers were initially searched, and 43 papers were included.
RESULTS AND CONCLUSION: The searched papers were summarized and analyzed. Chitosan and its ramifications can be as the carriers of protein, cytotoxic type, nucleic acid drugs and diagnostic reagent. Compared with the prototype drug, the nano-drug carrier showed longer in vivo circulation time, better drug effectiveness and little toxic side effect. Bioeffect and safety of in vivo drug effectiveness and biodistribution are different, and the research methods are also different. Chitosan shows the great potential as nano-drug carriers

中图分类号: